MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

DexCom Inc

Gesloten

SectorGezondheidszorg

68.23 1.43

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

66.46

Max

68.49

Belangrijke statistieken

By Trading Economics

Inkomsten

17M

152M

Verkoop

119M

1.1B

K/W

Sectorgemiddelde

47.409

63.778

EPS

0.45

Winstmarge

13.624

Werknemers

10,200

EBITDA

5M

242M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+53.59% upside

Dividenden

By Dow Jones

Volgende Winsten

24 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-7.9B

26B

Vorige openingsprijs

66.8

Vorige sluitingsprijs

68.23

Nieuwssentiment

By Acuity

15%

85%

26 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

DexCom Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 okt 2024, 09:10 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

26 jul 2024, 20:16 UTC

Winsten

These Stocks Moved the Most Today: DexCom, 3M, Nvidia, Bristol Myers, Coursera, Biogen, Charter, Deckers, and More -- Barrons.com

26 jul 2024, 09:13 UTC

Top Nieuws
Populaire aandelen

Stocks to Watch: DexCom, Coinbase, 3M, Hermès -- WSJ

26 jul 2024, 08:56 UTC

Top Nieuws

These Stocks Are Moving the Most Today: DexCom, Deckers, Coursera, Ford, Alphabet, Bristol Myers, 3M, and More -- Barrons.com

27 jun 2024, 16:01 UTC

Winsten

ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be. -- Barrons.com

Peer Vergelijking

Prijswijziging

DexCom Inc Prognose

Koersdoel

By TipRanks

53.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 103.4 USD  53.59%

Hoogste 120 USD

Laagste 82 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor DexCom Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

16

Buy

2

Hold

0

Sell

Technische score

By Trading Central

66.25 / 72.47Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

26 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.